Friday, December 5, 2014
10:20 - 11:50 |
HRT: WHO SHOULD BE TREATED?Organized by EMAS |
| Capsule |
While HT should probably not be started on older women we still need to have a more precised, personalized way to select the "right treatment to the right early postmenopausal woman". Where are we today?
|
| Chairperson |
Margaret Rees, UK
|
|
HRT: Who should be treated?
Sven Skouby, Denmark
|
|
| HRT revised in light of new evidence Serge Rozenberg, Belgium |
|
| Beneficial actions of progesterone including on the brain Regine Sitruk-Ware, France |
|
|
Pharmaceutical interventions at the time of menopause to reduce the incidences of breast cancer |
12:10 - 13:40 |
NEW COMBINATION IN THE MARKET |
Capsule |
Should we go back to prescribing HT to climacteric-symptomatic patients, or just combine SERMs and HT to enjoy the best of both worlds?
|
|
Chairpersons |
Sven Skouby, Denmark
|
|
Mechanism of action of the estrogens/bazedoxifene
Christian Egarter, Austria
|
|
|
Efficacy and sapfety of conjugated estrogens/bazedoxifene (CE/BZA)
Santiago Palacios, Spain
|
|
|
Positioning of estrogens/bazedoxifene in the treatment of menopausal women
Andrea Genazzani, Italy
|
|
|
HT and osteoporosis
Robert Langer, USA
|
14:30 - 16:00 |
TREATMENT OF MENOPAUSE |
| Capsule |
Aspects of hormonal treatment around menopause |
| Chairpersons |
Herjan Coelingh Bennink, Netherlands
Robert Langer, USA
|
|
Why don't we give COC users their androgens back?
Rik van Lunsen, Netherlands |
|
|
Sex steroids as anti-aging therapy for the women's brain
Andrea Genazzani, Italy
|
|
|
Contraception and menopaue
Alfred Mueck, Germany
|
|
|
Menopause, hormones, well-being and sexuality
Michèle Lachowski, France
|
16:30 - 18:00 |
MANAGING THE MENOPAUSAL SYMPTOMS
|
| Capsule |
Fungal infections of the vaginal tract account for a substantial number of medical consultations and recurrences that are due to mis-diagnosis and imprecise treatments. |
| Chairpersons | Santiago Palacios, Spain Alfred Mueck, Germany |
|
Vaginal Lactobacilli and biofilm formation
Gary Ventolini, USA
|
|
|
Pathogenic biofilms: Leading contibutors to recurrent vaginitis and cystitis
Alessandra Graziottin, Italy
|
|
|
Non-hormonal treatment of menopause
Santiago Palacios, Spain |
Saturday, December 6, 2014
08:30 - 10:00 |
OVARIAN CANCER
|
| Capsule | Ovarian cancer is among the deadliest gynecological diseases. Can we improve detection and survival by better screening tools? |
| Chairpersons | Richard G. Moore, USA Adam Rosenthal, UK |
|
Pelvic mass risk assessment: Do we need to operate on everyone?
Richard G. Moore, USA
|
|
|
BRCA gene mutation: When do we screen and when do we operate?
Adam Rosenthal, UK
|
|
|
Ovarian cancer screening in the general population: To screen or not to screen - What is the future?
Ian Jacobs, UK
|
|
|
The origin of ovarian cancer
Victor Gomel, Canada |
Workshop in HPV and adolescence gynecology
10:20 - 11:50 |
HPV SCREENING |
| Capsule |
Cervical cancer can be easily eliminated by HPV vaccination, so why is this still not universally applied and what are the concerns? A top international expert panel will address all the current issues, questions and misbeliefs
|
| Chairpersons |
Xavier Bosch, Spain
Chris J. Meijer, Netherlands
|
|
The regulation of HPV screening in Europe: Indication and trends.
Xavier Bosch, Spain
|
|
|
Out of 100+ available HPV tests, which are validated for screening/triage
Chris J. Meijer, Netherlands
|
|
|
The predictive value of HPV typing in screening vs. cocktail testing and typing as triage
Thomas Iftner, Germany |
|
|
Triage after HPV testing: The current role of cytology and other biomarkers
Quek Swee Chong, Singapore
|
|
|
DNA vs. mRNA tests
Thomas Ifner, Germany
|
|
|
Self-sampling the new frontier for screening coverage
Elmar Joura, Austria
|
|
|
Screening vaccinated women
Xavier Bosch, Spain
|
12:10 - 13:40 |
HPV VACCINATION AND COMBINED PROTOCOLS
|
| Chairpersons |
Xavier Bosch, Spain
Jorma Paavonen, Finland
|
|
How much disease will be avoided in vaccinated cohorts?
Elmar Joura, Austria
|
|
|
How much disease is avoided in vaccinated cohorts as recorded from population monitoring?
Jorma Paavonen, Finland
|
|
|
Boys and adult male vaccination
Elmar Joura, Austria
|
|
|
Substantial issue in vaccinology
Quek Swee Chong, Singapore
|
|
|
Vaccine safety
Jorma Paavonen, Finland
|
|
|
Integrated preventive approaches for women of all ages
Xavier Bosch, Spain
|
|
|
Screening and vaccination in The Nertherlands
Chris J. Meijer, Netherlands
|
14:30 - 16:00 |
A MULTIDIMENSIONAL GYNECOLOGICAL CARE OF ADOLESCENTS |
| Capsule |
It is common to trace the origin of some of endocrinopathies and adult gynecological symptoms to the adolescent years: Managing the un-met needs |
| Chairperson | Alessandra Graziottin, Italy Sven Skouby, Denmark |
|
The adolescent: A patient at risk
Charles Sultan, France
|
|
|
Consultation with the adolescent: More than a gynecological examination
George K. Creatsas, Greece
|
|
|
Deficiencies in the adolescent: Key supplementations
Santiago Palacios, Spain
|
16:30 - 18:00 |
CONTRACEPTION AND FAMILY PLANNING
|
Capsule |
Contraception before and after the reproductive years remains a challenge |
Chairpersons |
Charles Sultan, France
George K. Creatsas, Greece
|
|
Adolescence contraception
George Creatsas, Greece
|
|
|
Peri-menopausal use of 17Beta estradiol OC’s
Anne Gompel, France |
|
|
Medical termination of Pregnancy
Aubert Agostini, France
|